A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia

This is a multicentre, open-label study to assess the safety, tolerability, and efficacy of 0.5 mg Dutasteride administered once daily for 52 weeks in men with Androgenetic Alopecia types III vertex, IV and V per the Norwood-Hamilton classification. The study consists of a Screening Phase (3 weeks prior to Baseline) and a Treatment Phase (52 weeks). A subject who completes the full course of study treatment and the final study visit (Week 52; Visit 7) will be considered as study completion.


Eligibility Criteria:
Inclusion Criteria:

* Male outpatient, 20 to 50-years-old, inclusive (at the time of obtaining consent).
* AGA classified as Type III vertex, IV, or V (excluding Type IV anterior and V anterior) utilizing the Norwood-Hamilton classification.
* Fluent and literate in Japanese with the ability to comprehend and record information on the PAS SFI and DLQI questionnaires.
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \<2 x upper limit of normal (ULN); alkaline phosphatase and bilirubin \<=1.5 x ULN (isolated bilirubin \>1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is \<35%).
* Willing to comply with study requirements, including maintaining the same hair color and hairstyle throughout the study- a) subjects who use hair colorants/hair dyes may continue to do so; however, there should be no traces of hair color remaining on the scalp at the time of study visits. b) hair length in nonbalding areas should be \>=2 cm (0.75 inch) around the vertex region of the head at the time of study visits.
* Able to swallow and retain oral medication

Exclusion Criteria:

* Evidence of hypogonadism defined as serum testosterone \<250 Nanogram/decilitre (ng/dl) at Screening.
* Unstable liver disease (chronic stable hepatitis B and C are acceptable if subject otherwise meets entry criteria).
* History of renal insufficiency or Serum creatinine \>1.5 x ULN at Screening.
* History of malignancy within the past 5 years, except basal cell or squamous cell carcinoma of the skin.
* History of prostate cancer before the age of 50 years in a first degree relative.
* Serum PSA level \>2.0 nanogram/millilitre (ng/mL) at Screening.
* History of breast cancer or clinical breast examination suggestive of malignancy.
* Active unstable thyroid disease, including subjects on therapy for either hyperthyroidism or hypothyroidism unless their dose of thyroid medication has been stable for at least 3 months.
* Any unstable, serious co-existing medical condition(s) including, but not limited to, myocardial infarction, coronary bypass surgery, unstable angina, cardiac arrhythmias, clinically evident congestive heart failure, or cerebrovascular accident within 6 months prior to Screening; uncontrolled diabetes or peptic ulcer disease which is uncontrolled by medical management, and subjects who are known to be acquired immunodeficiency syndrome \[AIDS\](including subjects with a diagnosis of human immunodeficiency virus (HIV) positive).
* History or current evidence of any serious and/or unstable pre-existing medical or psychiatric disorder, or other conditions that could, in the opinion of the investigator or GSK medical monitor, interfere with the subject's safety, obtaining informed consent, or compliance with study procedures. Note: the investigator may consult with GSK medical monitor if a condition could interfere with the subject's safety.
* Clinically relevant abnormal finding on the Screening electrocardiogram (ECG).
* Global scalp hair thinning, including occipital areas.
* Scarring of the scalp, including prior hair transplant or scalp reduction, or any other condition or disease of the scalp or hair, including diseases of the hair shaft (e.g., tinea infection, nonandrogenetic-cause of alopecia, psoriatic dermatitis or other psoriatic lesions, or uncontrolled seborrheic dermatitis).
* History of hair transplantation at any time to correct AGA or use of hair weaving within 6 months prior to Screening.
* History or evidence of hair loss other than AGA (e.g., due to an auto-immune, endocrine, mechanical or infectious process, or secondary to a scalp dermatological disorder).
* Use of any cosmetic product aimed at improving or correcting the signs of hair loss (e.g., scalp preparations with claims aiming at improved hair growth) within 2 weeks prior to Screening.
* Use of light or laser treatments on the scalp (e.g., light emitting diode \[LED\] lamps) within 3 months prior to Screening.
* Hypersensitivity to any 5 alpha-reductase (5AR) inhibitor or drugs chemically related to the study treatment.
* Use of Dutasteride within 18 months prior to Screening, or use of finasteride within 12 months prior to Screening.
* Previous use of systemic cytotoxic agents.
* Use of glucocorticoids (inhaled glucocorticoids are allowed; topical corticosteroids are allowed provided that they are not used on the scalp) within 3 months prior to Screening.
* Use of the following during the 6 months prior to Screening: Minoxidil (oral or topical), Carpronium chloride, Systemic drugs with anti-androgenic properties (e.g., cyproterone acetate, spironolactone, ketoconazole, flutamide, and bicalutamide). Use of ketoconazole shampoo on the scalp is prohibited during the study, but use before Screening is not a reason for exclusion. Cimetidine is prohibited during the study, but use before Screening is not a reason for exclusion, Topical estrogen or progesterone, Topical prostaglandin analogs on the scalp, Tamoxifen, Drugs potentially causing hypertrichosis (e.g., cyclosporine, diazoxide, phenytoin, psoralens), Drugs potentially causing hypotrichosis or telogen effluvium (e.g., valproic acid), Anabolic steroids, Lithium or phenothiazines.
* Participation in any investigational or marketed drug or device trial within 1 month prior to Screening for this study. Including participation in any trial for Dutasteride and administration of active drugs (Dutasteride or finasteride) prior to Screening for this study. In addition, subjects must not participate in any other drug or device trials during the course of this study.